(0.58%) 5 076.00 points
(0.34%) 38 199 points
(0.82%) 17 581 points
(0.97%) $79.77
(2.38%) $1.978
(-0.02%) $2 310.50
(-0.46%) $26.63
(0.46%) $959.30
(0.19%) $0.935
(0.47%) $11.08
(0.10%) $0.799
(-1.49%) $91.87
0.23% £ 214.50
Live Chart Being Loaded With Signals
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States...
Stats | |
---|---|
Dzisiejszy wolumen | 22 765.00 |
Średni wolumen | 523 585 |
Kapitalizacja rynkowa | 579.60M |
EPS | £0 ( 2024-04-25 ) |
Następna data zysków | ( £0 ) 2024-06-12 |
Last Dividend | £0 ( N/A ) |
Next Dividend | £0 ( N/A ) |
P/E | -11.29 |
ATR14 | £0.890 (0.41%) |
Wolumen Korelacja
PureTech Health PLC Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
PureTech Health PLC Korelacja - Waluta/Towar
PureTech Health PLC Finanse
Annual | 2023 |
Przychody: | £750 000 |
Zysk brutto: | £750 000 (100.00 %) |
EPS: | £-0.240 |
FY | 2023 |
Przychody: | £750 000 |
Zysk brutto: | £750 000 (100.00 %) |
EPS: | £-0.240 |
FY | 2022 |
Przychody: | £2.09M |
Zysk brutto: | £2.09M (100.00 %) |
EPS: | £-0.130 |
FY | 2021 |
Przychody: | £17.39M |
Zysk brutto: | £0.00 (0.00 %) |
EPS: | £-0.214 |
Financial Reports:
No articles found.
PureTech Health PLC
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej